TRANSPLANT

MATRIX
LifeCell's Transplant Matrix enlists the
stem cell transplants performed using
the preserved umbilical cord samples
retrieved from LifeCell's laboratory. This
white paper elucidates a detailed
analysis of the samples retrieved through
statistical evidence including age range
of the patients, transplant type, sample
criteria and much more. This collective
information will help us understand how
cord blood banking contributes to
therapeutic care through stem cell
transplants.
Transplant Matrix

Total number of samples retrieved for transplant 45 Samples

Age range of patients who received the transplant

Youngest Patient Oldest Patient

6 months (Male)
st
(Male) 11 Years
st
(21 Case) (31 Case )
Spastic Cerebral Palsy Chronic Granulomatous Disease
Autologous Allogenic

Gender distribution

Male Female
26 Samples 19 Samples

Type of Transplants

Autologous: Uses patient’s own stem cells Allogenic: Uses donor stem cells

Autologous Allogenic
7 cases 38 cases
[ 6 - Spastic Cerebral Palsy
1 - Autism Spectrum Disorder [
06 Years 11 Years
25th & 45th Case 31st Case

Age distribution Age distribution

06 Months 08 Months in allogenic
in autologous 41st Case
21st Case samples
samples
Transplant Matrix

Distribution of HLA matching amongst siblings

Human Leukocyte Antigens are proteins on the surface of our cells that helps the immune
system to identify the cells that belong to our body. The best transplant outcome happens when
a patient's HLA and the donor's HLA closely match.

38 Cases with 6/6 match 24

Cases with 5/6 match 09
Cases with 4/6 match 05
ALLOGENIC CASES

HLA typing is used to match the compatibility of the patient with a donor for stem cell transplant
A 4 out of 6 HLA match (~67% match) between the patient and the donor is sufficient for umbilical
cord blood stem cell transplant while other stem cell sources may require 100% full match.

Reference: http://www.nationalcordbloodprogram.org/public_hla_search.html

Type of sample storage: Single & Dual Site Storage

For disaster management, sample back-up and added retention security, LifeCell offers an
exclusive two-site storage service which helps in the preservation of stem cell samples in
LifeCell's Chennai and Gurgaon facilities.

SINGLE DUAL
STORAGE 35 10 STORAGE

Gurgaon
Chennai Chennai

Of the 45 retrieved samples, 35 samples were preserved in LifeCell's Chennai laboratory alone
(Single Site Storage) and 10 samples were preserved at two sites - LifeCell's Chennai and
Gurgaon (Manesar) laboratories (Dual Site Storage).
 Transplant Matrix

Volume* of the preserved stem cell samples at the time of retrieval

Median Values Per Cord Blood Unit

39 cases
Median Collection Volume 91 ml
Median Storage Volume 25 ml
25mL
Median Volume Retrieved 25 ml
Median TNCC 601 Million
09mL Median CD34+ Cell Count 1.80 Million
06 cases
Median CD34+ Stem Cell Viability 95.12%

Volume distribution of the retrieved samples

35

30 05 ml : 01 case
Number Of Retrivals

25

20
09 ml : 06 cases

15
20 ml : 01 case
10

05
25 ml : 37 cases

05 10 15 20 25 30
Sample Volume

Sample preservation time before retrieval

Youngest Sample (CBU) Retrieved

4 months (0.3 years)
th
6 Case
4 Months Chronic Myeloid Leukemia (CML)

Oldest Sample (CBU) Retrieved

72 Months 72 months (6 years)
th
45 Case
Autism Spectrum Disorder

* At LifeCell, between 2004 to 2006, the processed cord blood units were stored in two cryo-vials of 4.5 mL each (total 9mL). With
continuous improvements in the CBU storage technology, from 2007 onwards, the processed cord blood units are being stored in
US FDA compliant special cryo-bags which are compartmentalized into 20 mL main bag and 5 mL pilot bag. This distribution
means greater flexibility for future sample access.
Transplant Matrix

Medical conditions treated using the retrieved Stem Cell Samples

Beta Thalassemia Major 32

Medical Cond
itions
Spastic Cerebral Palsy 06
32
Autism 01
06
Others 06 01
06

Acute Lymphoblastic Leukemia (ALL) 1

Acute Myeloid Leukemia (AML) 1
Chronic Myeloid Leukemia (CML) 1
Juvenile Myelomonocytic Leukemia (JMML) 1
Chronic Granulomatous Disease (CGD) 1
Hemophagocytic Lymphohistiocytosis (HLH) 1

Worldwide retrieval of samples

07

36
01
01

India 36 | USA 07 | Singapore 01 | Thailand 01

Transplant Matrix

List of hospitals that performed these transplants

Transplant Centers Retrievals

Apollo Speciality Hospital, Chennai, India 22

Dr. B. L. Kapur Memorial Hospital, Pusa Road, New Delhi, India 5
Narayana Hrudayalaya Health City, Bengaluru, India 3
Christian Medical College (CMC), Ludhiana, Punjab, India 2
Fortis Malar Hospital, Chennai, India 1
Sri Ganga Ram Hospital, Rajinder Nagar, New Delhi, India 1
Sterling  Hospital, Ahmedabad, India 1
Rajiv Gandhi Cancer Institute and Research Center, Delhi, India 1

Duke University Medical Center, Durham, NC, USA 5

Carolinas Cord Blood Bank at Duke University, USA 2

Mount Elizabeth Hospital, Singapore 1

Siriraj Hospital Medical School, Bangkok, Thailand 1

Physicians who performed these cord blood stem cell transplants

Transplant Physicians Retrievals

Dr. Revathi Raj, Apollo Speciality Hospital, Chennai, India 21

Dr. Dharma Choudhary, Dr. B. L. Kapur Memorial Hospital, New Delhi, India. 4
Dr. Joanne Kurtzberg, Carolinas Cord Blood Bank at Duke University, USA. 4
Dr. Jessica M. Sun, M.D., Duke University Medical Center, USA. 3
Dr. Sunil Bhat, Narayana Hrudayalaya Health City, Bengaluru, India 3
Dr. M. Joseph John, MD, DM, Christian Medical College, Ludhiana, Punjab, India. 2
Dr. Vinai Suwatte, Siriraj Hospital Medical School, Bangkok, Thailand. 1
Dr. Dinesh Bhurani, Sterling Hospital, Ahmedabad, India 1
Dr. Patrick Tan, Mount Elizabeth Hospital, Singapore. 1
Dr. Ranjan Kumar Mohapatra, Apollo Speciality Hospital, Chennai, India 1
Dr. Satya P. Yadav, Sri Ganga Ram Hospital, Rajinder Nagar, New Delhi, India. 1
Dr. V. Murugan, M.D., M RCPH (UK), CCT - UK, Fortis Malar Hospital, Chennai, India. 1
Dr. Gaurav Kharya, Dr. B. L. Kapur Memorial Hospital, Pusa Road, New Delhi, India. 1
Dr. Narendra Agrawal, Rajiv Gandhi Cancer Institute and Research Center, Delhi, India. 1
Transplant Matrix

Retrieval Matrix: Medical Condition (Diagnosis) vs. Country of Transplant

India USA Singapore Thailand

TOTAL
Medical Condition / Diagnosis

Acute Myeloid Leukemia (AML) 1 - - - 1

Chronic Myeloid Leukemia (CML) 1 - - - 1

Acute Lymphoblastic Leukemia (ALL) - 1 - - 1

Juvenile Myelomonocytic Leukemia (JMML) 1 - - - 1

Beta Thalassemia Major 30 - 1 1 32

Spastic Cerebral Palsy (CP) 1 5 - - 6

Chronic Granulomatous Disease (CGD) 1 - - - 1

Hemophagocytic Lymphohistiocytosis (HLH) 1 - - - 1

Autism Spectrum Disorder - 1 - - 1

Transplant Outcomes

Beta Thalassemia Major

On follow-up of 24 out of the first 30 cases, 95% of the patients were
found to have one-year disease free survival.

Reference: http://parentsguidecordblood.org/en/news/cord-blood-transplants-
95% thalassaemia-india

Spastic Cerebral Palsy

The children who participated in the Phase II randomized, placebo controlled trial received infusion
of their own cord blood. The results showed increased motor function at one year which was 30%
higher than predicted for the age and level of function scores. Researchers have suggested that
this data is sufficient to use autologous cord blood transplants for clinical purposes. However,
further studies are needed to confirm the results.

Reference: Excerpts from 'Cellular Horizon' International conference held at Vatican City from 28 – 30 April 2016 [unpublished
data]
 Transplant Matrix

Editorial Board About LifeCell

Brig (Dr.) Paramjit Dhot, VSM Established in 2004, LifeCell is India's first and largest
Medical Director stem cell bank, enjoying the trust of over 2 lakh parents
who have banked their children's stem cells with the
Dr. Chirayu Padhiar company. With state-of-the-art facilities and a spread
Laboratory Director over 200 centers in the country and footprints in GCC
countries, LifeCell is also the most recommended stem
Dr. SM. Salahudeen cell bank by gynaecologists. The company has
Vice President I Cellular Therapy accreditations from international organizations for
standards such as American Association of Blood
Mr. Vinesh Mandot Banks (AABB), College of American Pathologists (CAP),
Senior Manager - Sales Excellence WHO GMP and National Accreditation Board for Testing
& Calibration Laboratories (NABL), US FDA registration
among others. LifeCell is also the only player in the
industry providing comprehensive stem cell solutions
including menstrual stem cell banking, R&D and point-
of-care stem cell therapy for orthopaedic, vascular
specialties.

Disclaimer:
Banking cord blood does not guarantee treatment outcomes. The use of umbilical cord stem cells to treat a medical condition is the
decision of treating transplant physician based on the suitability of the treatment and whether the source of stem cells is autologous
(self) or allogenic (suitable donor- siblings of the same biological parents have a 25% chance of a perfect match and a 50% chance of a
partial match; biological parents have partial match). Currently, umbilical cord tissue stem cells are not approved for clinical use since
they are evaluated under clinical trials and hence its use depends on the ongoing research. There is no guarantee that treatments
studied in the laboratory, clinical trials and other experimental treatments (including regenerative medicine applications) shall be
available in the future.

©2016 LifeCell International Private Limited. All rights reserved.

LC/BC/WP-01/02-17/V003

LifeCell International Pvt. Ltd.

#26, Vandalur Kelambakkam Main Road,

Keelakottaiyur, Chennai, Tamil Nadu - 600127, India.
Call 1800 419 5555 | SMS 'LIFECELL' TO 53456 | Visit www.lifecell.in